{"id":101974,"date":"2020-10-01T09:53:51","date_gmt":"2020-10-01T09:53:51","guid":{"rendered":"https:\/\/www.edristi.in\/?p=101974"},"modified":"2020-10-01T09:53:52","modified_gmt":"2020-10-01T09:53:52","slug":"who-to-avail-affordable-quality-120-million-covid-19-rapid-tests","status":"publish","type":"post","link":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/who-to-avail-affordable-quality-120-million-covid-19-rapid-tests\/","title":{"rendered":"WHO to avail affordable, quality 120 million COVID-19 Rapid Tests"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Question: Which of the following, could not be a test for COVID-19-<\/strong><br>a) PCR based test<br>b) Rapid Antigen tests<br>c) Antibody tests<br>d) Rorschach test<br><strong>Answer: (d)<br>Related Facts:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>On 28 September, 2020 The World Health Organisation (WHO) made an announcement that it will provide about 120 million antigen rapid diagnostic tests in the months ahead.<\/li><li>These tests will be available to low- and middle-income countries (LMIC).<\/li><li>W.H.O has done milestone agreements for this purpose with the Abbott, SD Biosensor and the Gates Foundation.<\/li><li>WHO Director General Tedros Adhanom Ghebreyesus has made following announcement regarding new rapid testing kits-<\/li><li>This will enable the expansion of testing, particularly in hard-to-reach areas that do not have lab facilities or enough trained health workers to carry out PCR tests.<\/li><li>The tests are priced at a maximum of $5 per unit, substantially cheaper than PCR tests.<\/li><li>This also assured that there may be further coming down of testing costs.<\/li><li>To achieve this purpose Volume guarantee agreements have been signed with rapid diagnostic test producers Abbott and SD Biosensor and the Bill and Melinda Gates Foundation (BMGF).<\/li><li>WHO has declared that the tests provide reliable results in 15 to 30 minutes, as compared to a few hours or days, and at a lower price.<\/li><li>This is a vital addition to their testing capacity and is especially important in areas of high transmission.<\/li><li>It has been explained that the sooner Covid-19 is diagnosed, the quicker action can be taken to treat and isolate those with the virus and trace their contacts.<\/li><li>Why these test preferred by WHO<\/li><li>Portability<\/li><li>The tests developed by Abbott and SD Biosensor are portable, reliable and easy to administer.<\/li><li>According to the WHO through these kits, testing is possible in near-person, decentralized healthcare settings.<\/li><li>apid Antigen Testing for SARS-CoV-2:-<\/li><li>Rapid antigen tests are commonly used in the diagnosis of respiratory pathogens, including influenza viruses and respiratory syncytial virus (RSV).<\/li><li>The US. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for antigen tests that can identify SARS-CoV-2.<\/li><li>Antigen tests are immune assays that detect the presence of a specific viral antigen, which implies current viral infection.<\/li><li>Antigen tests are currently authorized to be performed on nasopharyngeal or nasal swab specimens placed directly into the assay\u2019s extraction buffer or reagent.<\/li><li>The currently authorized antigen tests are not restricted to use on persons of a certain age.<\/li><li>Antigen tests are relatively inexpensive and can be used at the point-of-care.<\/li><li>The currently authorized devices return results in approximately 15 minutes.<\/li><li>Antigen tests for SARS-CoV-2 are generally less sensitive than viral tests.<\/li><li>Viral tests are highly sensitive and able to detect nucleic acid using reverse transcription polymerase chain reaction (RT-PCR).<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Links:-<\/strong><br><a href=\"https:\/\/www.who.int\/news-room\/detail\/28-09-2020-global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-tests-for-low--and-middle-income-countries\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.who.int\/news-room\/detail\/28-09-2020-global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-tests-for-low&#8211;and-middle-income-countries<br><\/a><a href=\"https:\/\/www.thehindubusinessline.com\/news\/world\/who-to-offer-low-middle-income-nations-120-million-low-cost-rapid-antigen-tests-for-covid-19\/article32721488.ece\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.thehindubusinessline.com\/news\/world\/who-to-offer-low-middle-income-nations-120-million-low-cost-rapid-antigen-tests-for-covid-19\/article32721488.ece<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Question: Which of the following, could not be a test for COVID-19-a) PCR based testb) Rapid Antigen testsc) Antibody testsd) Rorschach testAnswer: (d)Related Facts: On 28 September, 2020 The World Health Organisation (WHO) made an announcement that it will provide about 120 million antigen rapid diagnostic tests in the months ahead. These tests will be [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":101975,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1137],"tags":[2541],"class_list":["post-101974","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mis","tag-miscellaneous-en"],"jetpack_publicize_connections":[],"jetpack_shortlink":"https:\/\/wp.me\/phvHKS-qwK","jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.edristi.in\/wp-content\/uploads\/2020\/10\/WHO-to-avail-affordable-quality-120-million-COVID-19-Rapid-Tests.png?fit=250%2C78&ssl=1","_links":{"self":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/101974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/comments?post=101974"}],"version-history":[{"count":1,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/101974\/revisions"}],"predecessor-version":[{"id":101976,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/101974\/revisions\/101976"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media\/101975"}],"wp:attachment":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media?parent=101974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/categories?post=101974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/tags?post=101974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}